Expanding cancer genomics to Arab populations
Cancer genomics has largely been built on data from people of White European ancestry. We worked with a Saudi genomics lab to close that gap for Arab communities, so screening and prevention work better for the people they serve.
The challenge
Most of what we know about cancer genetics comes from people of White European ancestry, which leaves Arab communities underrepresented in the reference data. That weakens genetic screening and preventive care. A Saudi genomics lab wanted to change that for familial cancers in their population.
What we set out to do
- Analyse genomic data from Saudi patients with familial cancers, and from their relatives
- Find population-specific variants in known cancer genes that may be pathogenic
- Describe the familial cancer patterns in the data
- Help the hospitals improve their screening protocols
- Give patients and clinicians a clearer basis to manage risk early
Our approach
Analysis framework
We built population-specific analysis pipelines, identified candidate variants, modelled the genetic distributions statistically and compared them against existing databases, then ran risk-assessment modelling on top.
Variant work and publication
We classified and researched the variants, set out the statistics behind the novel associations with familial cancers, and strengthened the manuscript after peer review by applying the statistical revisions the reviewers asked for.
Clinical integration
We worked with the clinical teams so the findings could feed into screening and care, and published the results to inform wider health policy.
Results and impact
We identified variants linked to prostate, colorectal and breast cancer that are specific to Arab populations, and mapped novel genetic patterns in familial cancers. The work produced two published, peer-reviewed papers, and supports more accurate risk assessment, better-targeted prevention and clearer family health planning.
“They were responsive, technically and statistically excellent, and a pleasure to work with. They exceeded our expectations in expanding genetic research for Arab populations.”
Related papers
Our team has co-authored peer-reviewed papers on cancer genomics in Saudi Arabian patients:
- The genomic landscape of colorectal cancer in the Saudi Arabian population using a comprehensive genomic panel (Diagnostics, 2023)
- Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel (Oncotarget, 2023)
- Clinicopathologic and genomic characterizations of brain metastases using a comprehensive genomic panel (Frontiers in Medicine, 2022)
See all of the team's papers on our publications page.
Timeline
- Initial analysis: around two weeks
- Implementation and manuscript submission: about a month
- Clinical integration: roughly three months
Looking forward
We are continuing with a second study, extending the analysis to more cancer types and helping develop broader screening protocols for diverse populations.
